The trial was designed to assess the efficacy and safety of semaglutide, a once-weekly subcutaneous glucagon-like peptide 1 (GLP-1) receptor agonist, in preventing major kidney outcomes, specifically kidney failure, substantial loss of kidney function, and death from kidney or cardiovascular causes, in individuals with type 2 diabetes and chronic kidney disease
(These drugs are known to carry a risk of pancreatitis and gallbladder disease.) Many of these people sought out medical care or were hospitalized
Predicting Diagnostic Progression to Schizophrenia or Bipolar Disorder via Machine Learning
PubMed Central Important Medical Information and Disclaimers MEDICAL DISCLAIMER This information is for educational purposes only and is not intended as medical advice, diagnosis, or treatment recommendation
InjectCo sources from licensed 503B pharmacies and requires a full provider evaluation before prescribing
Diminished Weight Loss Results The most common consequence of using expired semaglutide is that it simply stops working
